TNF and inflammatory bowel disease: Biologic agents such as the TNF‐α inhibitor infliximab have had a substantial, positive impact on the treatment of many chronic immune‐mediated inflammatory disorders, including inflammatory bowel diseases (IBD), inflammatory rheumatic diseases and chronic plaque psoriasis 1.